Alkermes Plc

Alkermes Plc is a leading biopharmaceutical company that is dedicated to developing innovative medicines for patients suffering from serious and chronic diseases. With a primary focus on central nervous system disorders, addiction, and oncology, Alkermes is committed to improving the lives of patients through the discovery, development, and commercialization of novel therapies. The company boasts a portfolio of FDA-approved products for schizophrenia, bipolar disorder, and opioid addiction, as well as a promising pipeline of candidates in various stages of development. Alkermes is committed to advancing science and delivering value to patients, healthcare providers, and shareholders alike.